From: Prevalence and determinants of controlled hypertension in a German population cohort
Female (N = 734) | Male (N = 1027) | Total (N = 1761) | ||||
---|---|---|---|---|---|---|
N/Ntot | % (95% CI 2 ) | N/Ntot | % (95% CI 2 ) | N/Ntot | % (95% CI 2 ) | |
Patients without risk-comorbidity 3 | (N = 487) | (N = 680) | (N = 1167) | |||
no antihypertensive drugs | 74/174 | 40.4 | 152/380 | 41.6 | 226/554 | 41.2 |
(33.0 – 47.8) | (36.4 – 46.8) | (37.0 – 45.5) | ||||
mono therapy | 58/122 | 46.5 | 36/129 | 31.4 | 94/251 | 39.1 |
(37.3 – 55.6) | (22.4 – 40.2) | (32.7 – 45.5) | ||||
combination therapy | 92/191 | 49.0 | 77/171 | 42.3 | 169/362 | 46.1 |
(41.4 – 56.6) | (34.1 – 50.5) | (40.5 – 51.6) | ||||
total | 224/487 | 45.1 | 265/680 | 39.8 | 489/1167 | 42.1 |
(40.6 – 49.7) | (35.8 – 43.8) | (39.1 – 45.1) | ||||
Patients with risk-comorbidity 4 | (N = 247) | (N = 347) | (N = 594) | |||
no antihypertensive drugs | 17/51 | 33.9 | 13/82 | 13.0 | 30/133 | 21.7 |
(20.5 – 47.3) | (5.6 – 20.4) | (14.5 – 28.9) | ||||
mono therapy | 8/39 | 21.8 | 3/56 | 5.8 | 11/95 | 12.5 |
(7.7 – 35.9) | (0.0 – 12.5) | (5.2 – 19.8) | ||||
combination therapy | 37/157 | 21.8 | 53/209 | 26.7 | 90/366 | 24.4 |
(15.7 – 27.9) | (19.0 – 34.5) | (19.4 – 29.5) | ||||
total | 62/247 | 24.5 | 69/347 | 19.6 | 131/594 | 21.7 |
(19.0 – 29.9) | (14.3 – 24.8) | (17.9 – 25.5) |